Financial Data and Key Metrics Changes - Year-over-year annual revenue decreased by $70.3 million, and quarterly revenue decreased by $15.6 million, primarily due to reduced revenue from the CSL collaboration and lower milestone achievements as KOSTAIVE was commercialized [14] - Annual and quarterly research and development expenses decreased by $83.0 million and $19.3 million, respectively, driven by lower manufacturing and clinical costs related to the LUNAR-COV19 program [15] - Cash equivalents and restricted cash were $232.8 million as of December 31, 2025, down from $293.9 million on December 31, 2024, extending the cash runway into the second quarter of 2028 [16] Business Line Data and Key Metrics Changes - The ARCT-032 program for cystic fibrosis is progressing with a phase II trial, with higher dose testing showing no safety concerns [5][10] - The ARCT-810 program for ornithine transcarbamylase deficiency is advancing toward pivotal development, with regulatory meetings scheduled for the first half of 2026 [6][12] - The KOSTAIVE COVID-19 vaccine program received approval from the U.K. Medicines and Healthcare Products Regulatory Agency in January 2026 [7] Market Data and Key Metrics Changes - The company is expanding its clinical trial sites internationally, including Europe and the Middle East, to enroll patients with specific CF genetic mutations [37] - The focus on rare disease clinical programs is expected to yield significant milestones in the near term [16] Company Strategy and Development Direction - The company aims to optimize its clinical studies by enhancing baseline stability and incorporating more sensitive measures like Lung Clearance Index (LCI) [20][21] - There is a strategic focus on both adult and pediatric populations for the OTC deficiency program, with plans to leverage recent FDA guidance for ultra-rare populations [45] - The company is committed to maintaining a strong financial position while pursuing multiple near-term value-creating milestones [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming 12-week CF study, emphasizing the importance of establishing a stable baseline for patient enrollment [50][51] - The company is actively engaging with regulatory authorities to clarify the path forward for both the CF and OTC deficiency programs [56] - Management highlighted the ongoing discussions with CSL regarding the KOSTAIVE collaboration and the challenges faced in progressing the vaccine to licensure in the U.S. [59] Other Important Information - The company is involved in a lawsuit against AbbVie and Capstan Therapeutics, which remains ongoing [8] - The management team includes key figures such as Joseph Payne (President and CEO) and Alan H. Cohen (Chief Medical Officer), who are leading the call and providing updates on various programs [3] Q&A Session Summary Question: What optimizations were included in the 12-week phase II study compared to the initial study? - Management highlighted differences in study design, including a focus on stable baseline lung function measures and the inclusion of LCI to enhance the signal-to-noise ratio [20][21] Question: How sensitive is the LCI test, and how does it correlate with other endpoints? - Management confirmed that LCI is more sensitive than traditional spirometry and is designed to measure early changes in lung function [28][29] Question: What is the rationale for stopping at 15 mg for the ARCT-032 study? - Management indicated that while 15 mg showed safety, the decision to proceed with 10 mg for the 12-week study was based on early efficacy signals observed at that dose [43][44] Question: What are the expected outcomes from the Type C meetings with regulatory authorities? - Management aims for clarity on study design and endpoints for both pediatric and adult populations in the OTC deficiency program [56][58] Question: What progress has been made regarding the KOSTAIVE vaccine? - Management reported that KOSTAIVE received approval in the U.K., but progress in the U.S. has been challenging due to the current administration's stance [59]